Indaptus Therapeutics Inc INDP 深 滬
已收盤 10-24 16:00:00 美东时间
3.63
+0.080
+2.25%
華盛通- 最 高3.72
- 今 開3.65
- 成交量 3.64万股
- 最 低 3.53
- 昨 收 3.55
- 總市值 401.66万
- 52周最高 47.60
- 市盈率 靜 --
- 換手率 3.29%
- 52周最低 2.22
- 委 比 66.67%
- 總股本 110.65万
- 歷史最高 21952.00
- 量 比 0.42
- 振 幅 5.35%
- 歷史最低 3.53
- 每 手 1
- 風險率 9.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
10-17 17:55
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
09-27 01:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agentNEW YORK,
09-05 04:02
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics announced updates on their INDP-D101 clinical trial for Decoy20, a potential cancer treatment. In monotherapy, a patient with urothelial cancer and liver metastases experienced partial response, though disease progression led to discontinuation. In combination with PD-1 inhibitor tislelizumab, safety profiles align with each agent. Initial data on 7 patients in the combination cohort show varied outcomes. Financially, the co...
09-04 20:01
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics CEO Jeffrey Meckler will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:30 PM ET in Kennedy I (4th Floor), Lotte New York Palace Hotel. A live webcast will be available on the company's investor relations website, with a replay archived for 90 days. Meckler will discuss the company's innovative immunotherapy platform, which uses a multi-targeted approach to activate immune ...
09-02 20:05
Indaptus Therapeutics Q2 EPS $(9.09) Beats $(9.24) Estimate
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(9.09) per share which beat the analyst consensus estimate of $(9.24) by 1.62 percent. This is a 30.93 percent increase over losses of $(13.16) per share
08-13 20:11
Indaptus Therapeutics Secures Approval for Private Placement
Indaptus Therapeutics ( ($INDP) ) just unveiled an announcement. Indaptus Thera...
07-30 04:58
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
